2022 News & Press Releases
SANTA FE SPRINGS, Calif.–(BUSINESS WIRE)–
Applied BioCode announced today that Chris Bernard has been appointed as their new Chief Executive Officer (CEO). Mr. Bernard joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic tests in the respiratory and gastrointestinal markets, along with the new SARS-CoV-2 Flu Plus Assay EUA approval, the company is continuing to scale its commercial business in providing transformative solutions for high throughput molecular diagnostics.
Chris Bernard brings 27 years of strong commercial, operational, and R&D leadership experience in diagnostics and medical devices to Applied BioCode. Most recently Chris was CEO of Oncogenesis Inc., a startup in oncology diagnostics, and Curetis USA Inc., (Opgen Inc.), a multiplex, infectious disease diagnostic company. He also has held various commercial executive roles at Epic Sciences Inc., Metabolon Inc., Abaxis Inc. (Zoetis Inc.), and Cytyc Corp (Hologic Inc.). His extensive experience will be key in evaluating current and emerging opportunities as the company enters its next phase of commercial expansion.
“The Applied BioCode team has developed a really innovative, multiplex PCR-based technology and the platform is uniquely positioned in the marketplace,” said Mr. Bernard. “I look forward to leading the company into our next phase of growth and long-term success. I am also excited to collaborate with Dr. Winston Ho, President, and the Board of Directors as we execute on the vision of delivering a cost-effective diagnostic platform that is designed to optimize workflow and alleviate pain points for mid to high throughput PCR labs.”
“Applied BioCode was founded to develop digital multiplex technology, broaden access, increase efficiencies, and reduce the cost of diagnostic testing,” explained Dr. Ho. He added, “As a scientist by training, my passion lies in forging the technology and innovation that will allow Applied BioCode to grow based on a very solid body of knowledge. Chris has an outstanding background and I’m confident his addition to the team will propel us forward to an even brighter future.”
Board Chairman, George J. Lee, Ph.D., commented, “With his fresh perspective and leadership, Chris will work closely with Dr. Ho to deliver on the company’s global strategy and mission as a molecular diagnostics company, through product development, commercialization, and strategic alliances.”